Luke Frazier supports a range of clients with evidence-based research and analysis on healthcare policy developments.

He applies his background in public policy and healthcare public affairs advising clients on the impact of policy to industry, with a particular focus on global and US vaccine policy as well as Medicare Part B.

Prior to joining Avalere, Luke held a variety of internship positions, including an apprenticeship with Schmidt Public Affairs where he drafted healthcare issue briefs and opinion editorials that were placed in major national publications and crafted messaging strategy for client campaigns. Additionally, he interned in the offices of Senator Tina Smith and Governor Mark Dayton where he worked in the areas of healthcare, agriculture, and Native American affairs researching policy issues and briefing staff on relevant topics.

Luke has a BA in international affairs from the George Washington University.

Authored Content

A new claims-based analysis from Avalere examined vaccine uptake among low-income adolescents enrolled in Medicaid Managed Care and found a 26% decline in routine vaccinations when comparing March–October 2019 to the same period in 2020.

New Avalere analysis finds that the the Most Favored Nation (MFN) Model would have a significant negative impact on Medicare providers that furnish Part B drugs—especially in oncology and rheumatology—and those in rural areas.

Tune into another episode of Avalere’s Journal Club Review podcast series on Avalere Health Essential Voice. In this segment, our health policy experts discuss a recent study in which a simulation was used to determine whether pull funding could overcome issues related to speed, scaling, and pricing for a COVID-19 vaccine.

On September 13, the Trump Administration released the much-anticipated “Most Favored Nation” (MFN) Executive Order (EO), calling for models that would cap the price Medicare pays for select Part B and D drugs. The President’s EO underscores the administration’s continued focus on reducing prescription drug price disparities between the US and other developed countries.